[ad_1]
The two companies reassured, explaining in a press release on Wednesday that they had developed shipping boxes for the Corona vaccine, to ensure that the doses were transported in a “safe and sound” manner.
The two companies explained that these crates were specially designed to control temperature and ensure safe storage conditions.
Concerns have been raised regarding the transfer and storage of Pfizer vaccine as it must remain at a temperature of about 75 degrees Celsius below zero, which is very low temperatures that are difficult to ensure under certain circumstances and in certain circumstances. country.
The insurance comes as the two companies said Britain’s Medicines and Healthcare Products Regulatory Agency has granted a temporary license to use the vaccine.
This is the first authorization for urgent use of the vaccines “Pfizer” and “Biontech”, after the completion of the third phase of clinical trials.
Additional licenses
The two companies expect to obtain more licenses from around the world in the coming days and weeks, and have announced that they are fully prepared to deliver vaccine doses after obtaining licenses and possible regulatory approvals.
The company said, “Biontech”, that the introduction of the Corona vaccine in Britain “will help reduce the number of hospital patients with high risk cases”.
40 million doses will be delivered in 2020 and 2021 in stages, to ensure that vaccines are distributed fairly and equitably between different regions in accordance with eligible legal contracts.
The first shipment of vaccines is expected to arrive in the UK in the coming days, with vaccines due in full delivery in 2021.
On Tuesday, the European Medicines Agency announced that it would hold a meeting on December 29 to decide on the adequacy of the safety and efficacy data for the “Covid-19” vaccine, which was developed by “Pfizer” and “Biontech”, for approval.
The agency said in a statement that on January 12 it would make a decision regarding the approval of an experimental vaccine against the emerging corona virus developed by the company “Moderna”.
The agency responsible for regulating the entry of medicines into the European Union has said it has already started a “continuous review” of the vaccine based on laboratory data previously provided by “Moderna”, and will assess now data on the vaccine’s effectiveness in eliciting an immune response and its effectiveness in use throughout Europe.
[ad_2]
Source link
